Benign Growth For RemeGen Co., Ltd. (HKG:9995) Underpins Stock's 41% Plummet
Jul 22
Hong Kong (HSI) Biotech Industry Analysis
UpdatedJul 24, 2024
DataAggregated Company Financials
Companies48
- 7D-0.1%
- 3M-4.9%
- 1Y-33.0%
- YTDn/a
Over the last 7 days, the Biotech industry has risen 1.8%, driven by gains from Innovent Biologics of 2.5%. In the same time, RemeGen was down 10%. In the past year, the industry is down 30%. As for the next few years, earnings are expected to grow by 35% per annum.
Industry Valuation and Performance
Has the Hong Kong Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Wed, 24 Jul 2024 | HK$322.8b | HK$49.6b | -HK$19,418,195,713.85 | 12.3x | -16.6x | 6.5x |
| Fri, 21 Jun 2024 | HK$332.5b | HK$49.7b | -HK$19,448,990,522.83 | 11.4x | -17.1x | 6.7x |
| Sun, 19 May 2024 | HK$370.2b | HK$49.8b | -HK$19,398,952,876.68 | 12.1x | -19.1x | 7.4x |
| Tue, 16 Apr 2024 | HK$334.7b | HK$49.6b | -HK$19,903,440,471.84 | 11x | -16.8x | 6.8x |
| Thu, 14 Mar 2024 | HK$364.5b | HK$47.3b | -HK$20,348,874,667.32 | 17.8x | -17.9x | 7.7x |
| Sat, 10 Feb 2024 | HK$322.5b | HK$46.8b | -HK$20,190,080,935.32 | 15.6x | -16x | 6.9x |
| Mon, 08 Jan 2024 | HK$376.7b | HK$47.0b | -HK$20,300,331,811.00 | 16.9x | -18.6x | 8x |
| Wed, 06 Dec 2023 | HK$413.2b | HK$47.0b | -HK$20,307,662,700.00 | 18.4x | -20.3x | 8.8x |
| Fri, 03 Nov 2023 | HK$414.7b | HK$45.1b | -HK$18,893,824,560.00 | 13x | -21.9x | 9.2x |
| Sun, 01 Oct 2023 | HK$400.6b | HK$45.0b | -HK$19,138,973,954.00 | 13.9x | -20.9x | 8.9x |
| Tue, 29 Aug 2023 | HK$383.9b | HK$39.2b | -HK$20,777,976,857.00 | 16.1x | -18.5x | 9.8x |
| Thu, 27 Jul 2023 | HK$408.9b | HK$35.6b | -HK$23,402,270,550.00 | 26.7x | -17.5x | 11.5x |
| Sat, 24 Jun 2023 | HK$386.4b | HK$35.5b | -HK$23,392,266,748.00 | 24.1x | -16.5x | 10.9x |
| Mon, 22 May 2023 | HK$427.6b | HK$36.2b | -HK$23,886,097,959.00 | 31x | -17.9x | 11.8x |
| Wed, 19 Apr 2023 | HK$458.8b | HK$37.0b | -HK$24,188,327,593.00 | 18.6x | -19x | 12.4x |
| Fri, 17 Mar 2023 | HK$405.3b | HK$33.1b | -HK$36,313,868,184.00 | 23.2x | -11.2x | 12.3x |
| Sun, 12 Feb 2023 | HK$441.6b | HK$34.8b | -HK$35,220,381,302.00 | 29.1x | -12.5x | 12.7x |
| Tue, 10 Jan 2023 | HK$436.7b | HK$34.8b | -HK$35,156,352,187.00 | 30.3x | -12.4x | 12.6x |
| Thu, 08 Dec 2022 | HK$361.4b | HK$33.5b | -HK$33,746,572,965.00 | 22.6x | -10.7x | 10.8x |
| Sat, 05 Nov 2022 | HK$354.8b | HK$33.3b | -HK$32,007,557,322.00 | 18.7x | -11.1x | 10.6x |
| Mon, 03 Oct 2022 | HK$286.2b | HK$34.0b | -HK$32,533,835,264.00 | 17x | -8.8x | 8.4x |
| Wed, 31 Aug 2022 | HK$323.9b | HK$33.6b | -HK$36,834,969,115.00 | 15.9x | -8.8x | 9.6x |
| Fri, 29 Jul 2022 | HK$336.0b | HK$32.8b | -HK$46,232,023,694.00 | 13.5x | -7.3x | 10.2x |
| Sun, 26 Jun 2022 | HK$383.4b | HK$33.1b | -HK$46,719,776,226.00 | 14.7x | -8.2x | 11.6x |
| Tue, 24 May 2022 | HK$348.6b | HK$34.1b | -HK$45,992,673,559.00 | 14.1x | -7.6x | 10.2x |
| Thu, 21 Apr 2022 | HK$337.5b | HK$36.3b | -HK$46,072,641,886.00 | 13x | -7.3x | 9.3x |
| Sat, 19 Mar 2022 | HK$320.7b | HK$34.8b | -HK$31,152,284,401.00 | 13.1x | -10.3x | 9.2x |
| Mon, 14 Feb 2022 | HK$293.8b | HK$31.1b | -HK$31,888,382,762.00 | 12.6x | -9.2x | 9.4x |
| Wed, 12 Jan 2022 | HK$367.5b | HK$31.1b | -HK$31,781,404,768.00 | 13.2x | -11.6x | 11.8x |
| Fri, 10 Dec 2021 | HK$483.1b | HK$31.2b | -HK$31,934,050,604.00 | 13.9x | -15.1x | 15.5x |
| Sun, 07 Nov 2021 | HK$449.2b | HK$30.9b | -HK$31,620,779,940.00 | 13.9x | -14.2x | 14.5x |
| Tue, 05 Oct 2021 | HK$495.3b | HK$30.5b | -HK$31,542,189,750.00 | 14.9x | -15.7x | 16.2x |
| Thu, 02 Sep 2021 | HK$520.5b | HK$30.2b | -HK$32,058,827,347.35 | 17.6x | -16.2x | 17.2x |
| Sat, 31 Jul 2021 | HK$562.1b | HK$30.2b | -HK$32,058,827,347.35 | 13.3x | -17.5x | 18.6x |
Price to Earnings Ratio
-17.5x
Current Industry PE
- Investors are pessimistic on the Hong Kong Biotechnology industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 10.7x is higher than the industry's current PS ratio of 6.7x.
Past Earnings Growth
- The earnings for companies in the Biotechnology industry have improved over the last three years.
- Revenues for these companies have grown 18% per year.
- This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.
Industry Comparison
How does Hong Kong Biotech compare with similar industries?
| HK Market | -2.37% | |
| Healthcare | -0.19% | |
| Biotech | -0.13% | |
| Biotech | -0.13% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 1801 Innovent Biologics | HK$40.85 | 2.5% +HK$1.6b | 20.0% | PS10x | |
| 9926 Akeso | HK$40.70 | 3.7% +HK$1.3b | 4.2% | PE16.2x | |
| 6990 Sichuan Kelun-Biotech Biopharmaceutical | HK$152.10 | 1.6% +HK$534.8m | 78.9% | PS20.5x | |
| 2509 Qyuns Therapeutics | HK$22.25 | 6.7% +HK$310.9m | n/a | PS312.1x | |
| 2487 Cutia Therapeutics | HK$7.70 | 8.6% +HK$183.1m | -62.4% | PS15.9x |
